Sponsored by:

Duke MMIL designs novel SPECT/CT system for 3D breast imaging

Jul 17, 2007
2007 07 17 14 38 39 706
2007 07 17 14 38 39 706
Image courtesy of Duke University Medical Center Multi-Modality Imaging Lab.

close

Latest in Molecular Imaging
(A) System comprises detectors and silicon photomultipliers with custom Hoffman brain phantom. (B) Seated-position scanning. (C) Backpack system permitting data collection in ambulatory states. (D) Workstation scenario demonstrating natural seated use.
Chinese scientists develop wearable brain PET system
May 1, 2026
Adobe Stock 107601498
NET tracers first widened, then closed imaging access gap
April 30, 2026
Molecular Imaging News Platform: trends, insights, professional views.
Sponsored
Molecular Imaging News Platform: trends, insights, professional views.
April 14, 2026
Quantification of total tumor volume (TTV) at lutetium-177 prostate-specific membrane antigen (PSMA)–617 SPECT/CT shows heterogeneous TTV responses between dose 1 (Cycle #1) and dose 2 (Cycle #2) in participants with metastatic castration-resistant prostate cancer. Posttherapy coronal attenuation-corrected noncontrast SPECT/CT maximum intensity projection images demonstrate (A) near-complete response in a 76-year-old man, (B) complete response in an 83-year-old man, (C) partial TTV reduction (not complete response) in a 69-year-old man, and (D) TTV increase (i.e. progressive disease) in a 74-year-old man. Blue-shaded regions represent semiautomatically segmented PSMA-avid tumor volume, with associated TTV values given at the bottom of each panel. The gradient bar shows standardized uptake value (SUV) from 0 to 5.
Lu-177 PSMA-SPECT/CT predicts survival in mCRPC
April 29, 2026
Related Stories
2007 07 17 15 08 50 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 07 17 14 32 28 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 06 25 10 54 15 706
Molecular Imaging
Studies link Alzheimer's to beta-amyloid and potential for new ligand
Molecular Imaging News Platform: trends, insights, professional views.
Sponsor Content
Molecular Imaging News Platform: trends, insights, professional views.
More in Molecular Imaging
Chinese scientists develop wearable brain PET system
By Will Morton
The system could offer new opportunities for brain PET imaging beyond the constraints of conventional static systems.
May 1, 2026
(A) System comprises detectors and silicon photomultipliers with custom Hoffman brain phantom. (B) Seated-position scanning. (C) Backpack system permitting data collection in ambulatory states. (D) Workstation scenario demonstrating natural seated use.
NET tracers first widened, then closed imaging access gap
By Will Morton
Ga-68 DOTATATE/DOTATOC captured 33.8% market share in its 2017 debut and reached 90.9% by 2020.
April 30, 2026
Adobe Stock 107601498
Serac highlights study on 99mTc-maraciclatide for endometriosis care
By AuntMinnie.com staff writers
Serac Healthcare is highlighting success from a study that evaluated the company's gamma-emitting radiotracer, 99mTc-maraciclatide.
April 30, 2026
Endometriosis 3 D Illustration 400
Lu-177 PSMA-SPECT/CT predicts survival in mCRPC
By Will Morton
Lu-177 PSMA-617 SPECT/CT total tumor volume complete response at six weeks associated with overall survival.
April 29, 2026
Quantification of total tumor volume (TTV) at lutetium-177 prostate-specific membrane antigen (PSMA)–617 SPECT/CT shows heterogeneous TTV responses between dose 1 (Cycle #1) and dose 2 (Cycle #2) in participants with metastatic castration-resistant prostate cancer. Posttherapy coronal attenuation-corrected noncontrast SPECT/CT maximum intensity projection images demonstrate (A) near-complete response in a 76-year-old man, (B) complete response in an 83-year-old man, (C) partial TTV reduction (not complete response) in a 69-year-old man, and (D) TTV increase (i.e. progressive disease) in a 74-year-old man. Blue-shaded regions represent semiautomatically segmented PSMA-avid tumor volume, with associated TTV values given at the bottom of each panel. The gradient bar shows standardized uptake value (SUV) from 0 to 5.
PET improves treatment planning for pituitary tumors
By Will Morton
Ga-68 DOTATATE PET altered radiation treatment volumes by nearly 20% compared with MRI alone.
April 28, 2026
A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).
PharmaLogic opens PET radiopharmaceutical facility in Atlanta
By AuntMinnie.com staff writers
PharmaLogic Holdings has opened a PET radiopharmaceutical manufacturing facility in Atlanta.
April 28, 2026
Georgia Atlanta Map Pin
C-Ray Therapeutics wins FDA active status for Cu-64 drug master file
By AuntMinnie.com staff writers
C-Ray Therapeutics has received active status from the FDA for its Type II Drug Master File for Cu-64 chloride for radiolabeling.
April 28, 2026
Fda Button 400
Plus Therapeutics beefs up manufacturing with SpectronRx
By AuntMinnie.com staff writers
Partnership supports 2026 radiopharmaceutical supply goal.
April 27, 2026
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
ChatGPT matches nuclear medicine experts on FDG-PET/CT scans
By Will Morton
Models excelled on cases with well-defined metabolic patterns, such as in typical cases of Alzheimer's disease, yet were less accurate on complex cases.
April 24, 2026
Ai Face
TAG1, NRG Pallas to advance Pb-212 supply for cancer therapies
By AuntMinnie.com staff writers
TAG1 and NRG Pallas aim to develop access to lead-212 (Pb-212) for cancer drug development across Europe.
April 22, 2026
A Rk Nx1 Fop15 Je H Jffj8rq D13
Ionetix raises $30M to scale radioisotope production
By AuntMinnie.com staff writers
The funding will support scaling up of radioisotope production as well as R&D efforts in nuclear energy, materials testing, and related areas.
April 21, 2026
Isotopes1
FAPI-PET superior to FDG-PET in liver cancer
By Will Morton
The finding is from a prospective head-to-head comparison among 59 patients with suspicious lesions.
April 20, 2026
A 65-y-old man with HCC and liver cirrhosis confirmed by MRI. Ga-68 FAPI-46 PET/CT demonstrates increased focal uptake (SUVmax, 13.26, and TBRmax, 2.89) in liver, whereas F-18 FDG-PET/CT scans showed non–F-18 FDG-avid lesion (SUVmax, 3.24, and TBRmax, 1.43), indicated by solid arrows. Additionally, histologically proven adenocarcinoma in colon transversum was identified as pathologic with Ga-68 FAPI-46 alone (dashed arrows).
Page 1 of 625
Next Page